These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 28289245)

  • 1. Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.
    Venkatesan S; Swanton C; Taylor BS; Costello JF
    Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28289245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment resistance in urothelial carcinoma: an evolutionary perspective.
    Vlachostergios PJ; Faltas BM
    Nat Rev Clin Oncol; 2018 Aug; 15(8):495-509. PubMed ID: 29720713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.
    Marusyk A; Janiszewska M; Polyak K
    Cancer Cell; 2020 Apr; 37(4):471-484. PubMed ID: 32289271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
    Gerlinger M; Swanton C
    Br J Cancer; 2010 Oct; 103(8):1139-43. PubMed ID: 20877357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer heterogeneity: converting a limitation into a source of biologic information.
    Rübben A; Araujo A
    J Transl Med; 2017 Sep; 15(1):190. PubMed ID: 28886708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic heterogeneity and cancer drug resistance.
    Turner NC; Reis-Filho JS
    Lancet Oncol; 2012 Apr; 13(4):e178-85. PubMed ID: 22469128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
    Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
    Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
    Kohsaka S; Petronczki M; Solca F; Maemondo M
    Future Oncol; 2019 Feb; 15(6):637-652. PubMed ID: 30404555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constraints in cancer evolution.
    Venkatesan S; Birkbak NJ; Swanton C
    Biochem Soc Trans; 2017 Feb; 45(1):1-13. PubMed ID: 28202655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of genetic heterogeneity in cancer.
    Schmitt MW; Prindle MJ; Loeb LA
    Ann N Y Acad Sci; 2012 Sep; 1267():110-6. PubMed ID: 22954224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drivers of dynamic intratumor heterogeneity and phenotypic plasticity.
    Biswas A; De S
    Am J Physiol Cell Physiol; 2021 May; 320(5):C750-C760. PubMed ID: 33657326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
    Murtaza M; Dawson SJ; Tsui DW; Gale D; Forshew T; Piskorz AM; Parkinson C; Chin SF; Kingsbury Z; Wong AS; Marass F; Humphray S; Hadfield J; Bentley D; Chin TM; Brenton JD; Caldas C; Rosenfeld N
    Nature; 2013 May; 497(7447):108-12. PubMed ID: 23563269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour heterogeneity and resistance to cancer therapies.
    Dagogo-Jack I; Shaw AT
    Nat Rev Clin Oncol; 2018 Feb; 15(2):81-94. PubMed ID: 29115304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenges of tumor genetic diversity.
    Mroz EA; Rocco JW
    Cancer; 2017 May; 123(6):917-927. PubMed ID: 27861749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational implications of tumor heterogeneity.
    Jamal-Hanjani M; Quezada SA; Larkin J; Swanton C
    Clin Cancer Res; 2015 Mar; 21(6):1258-66. PubMed ID: 25770293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumor heterogeneity: evolution through space and time.
    Swanton C
    Cancer Res; 2012 Oct; 72(19):4875-82. PubMed ID: 23002210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering Multidimensional Evolutionary Forces to Combat Cancer.
    McCoach CE; Bivona TG
    Cancer Discov; 2019 May; 9(5):587-604. PubMed ID: 30992280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
    Berns K; Bernards R
    Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.
    McGranahan N; Swanton C
    Cell; 2017 Feb; 168(4):613-628. PubMed ID: 28187284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.